Table 1.

Survey of portfolio-based nonprofit biomedical firms, 2008

Name	Primary purpose	Primary population focus	Primary disease focus	Products in clinical trials/approved	Year of formation	Annual budget	Major grants
Institute for Applied Biomedicine (http://www.appliedbiomed.org)	Financing, development, preclinical testing	Global health	Immune system–based treatments for HIV, autoimmune disorders	Immudel-gp120	1996	$31,236
Global Solutions for Infectious Diseases (http://www.gsid.org)	Financing, development, and testing	Global health	HIV vaccine, pediatric dengue vaccine		2004	$1,019,073	Gates Foundation, $7.9 million (2006, HIV)
Institute for OneWorld Health (http://www.iowh.org)	Financing, development, and testing	Global health	Anti-infectives	Artemisinic acid/paromomycin i.m. injection	1998	$23,391,795	Gates Foundation, $42.5 million (2004, artemisin); Gates Foundation, $10 million (2005, paromomycin); Gates Foundation, $46 million (2006, antidiarrhea program)
International Partnership for Microbicides (http://www.ipm-microbicides.org)	Financing, coordination, development, delivery	Women, global health	HIV transmission prevention	Dapivirine, L’644	2002	$18,775,834
Alfred Mann Foundation (http://www.aemf.org)	Financing, development, and testing	Developed world	Physical medical impairments	Glucose sensor, cochlear implant, implantable microstimulator	1985	$20,735,358
Institute for Pediatric Innovation (http://www.pediatricinnovation.org)	Financing, development, and testing	Children, developed world	Pediatric NICU, pediatric cardiology		2006	$43,260

Primary sources: Initiative for Public-Private Partnerships for Health (http://www.globalforumhealth.org) and GuideStar (http://www.guidestar.org); secondary sources: IRS 501(c)(3) records (http://www.irs.gov) and searches of individual companies’ websites. NICU, neonatal intensive care unit.